Overcoming T-cell-mediated immunopathology to achieve safe respiratory syncytial virus vaccination

Author： Castilow Elaine M   Varga Steven M  

Publisher： Future Medicine

ISSN： 1746-0794

Source： Future Virology, Vol.3, Iss.5, 2008-09, pp. : 445-454

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impairment of T Cell Immunity by the Respiratory Syncytial Virus: Targeting Virulence Mechanisms for Therapy and Prophylaxis

By  

Current Medicinal Chemistry, Vol. 16, Iss. 34, 2009-12 ,pp. : 4609-4625

Bentham Science Publishers

Access to resources Recommend Favorite

Immune-mediated disease pathogenesis in respiratory syncytial virus infection

By Graham B.S.   Johnson T.R.   Peebles R.S.  

Immunopharmacology, Vol. 48, Iss. 3, 2000-07 ,pp. : 237-247

Elsevier

Access to resources Recommend Favorite

Respiratory syncytial virus antiviral agents

By Prince G.A.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 6, 1999-06 ,pp. : 753-762

Informa Healthcare

Access to resources Recommend Favorite

Development of respiratory syncytial virus vaccines

By  

Inpharma, Vol. 1, Iss. 1429, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Impact of Respiratory Syncytial Virus: The Nurse's Perspective

By Bracht Marianne  

Drugs in R&D, Vol. 11, Iss. 3, 2011-09 ,pp. : 215-226

Adis International

Access to resources Recommend Favorite